Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2023-11-15 13:13:57 ET More on Merck, Pfizer, etc. Pfizer: Victim Of Vaccine Side Effects High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal Pfizer Inc. (PFE) Presents at Truist Securities BioPharma Symposium (Transcript) Pfizer to shed 500 ...
2023-11-12 22:45:00 ET Summary Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US and EU in 2024 could significantly broaden bempedoic...
2023-10-31 09:33:16 ET More on Daiichi Sankyo Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations Merck to pay up to $22B in cancer drug deal with Daiichi Sankyo As...
2023-10-30 07:39:24 ET More on Deciphera Deciphera Pharmaceuticals Pipeline Is Underwhelming Deciphera Pharmaceuticals: Clawing Its Way Back Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Deciphe...
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 07:05:54 ET More on Merck Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript) Merck Q3 2023 Earnings Preview: Keytruda LOE Continues To Dominate Narrative Merck: Right On Time ...
2023-10-23 09:02:58 ET Summary Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in development, targeting HER3, B7-H3, and CDH6, have shown pro...
2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...
2023-10-22 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We have been surprised...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...